GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » Research & Development

Jacobio Pharmaceuticals Group Co (HKSE:01167) Research & Development : HK$380.21 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Jacobio Pharmaceuticals Group Co's Research & Development for the six months ended in Jun. 2024 was HK$190.36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was HK$380.21 Mil.


Jacobio Pharmaceuticals Group Co Research & Development Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co Research & Development Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 154.65 220.43 343.88 497.66 407.24

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.00 300.46 217.39 189.85 190.36

Jacobio Pharmaceuticals Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$380.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobio Pharmaceuticals Group Co  (HKSE:01167) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Jacobio Pharmaceuticals Group Co Research & Development Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobio Pharmaceuticals Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.
Executives
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Vi, L.p. 2101 Beneficial owner
Qiming Gp Vi, L.p. 2201 Interest of corporation controlled by you
Wang Yinxiang 2501 Other
Wang Xiaojie 2307 Founder of a discretionary trust who can infl
Hu Yunyan 2501 Other
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Spr-iii Holdings Limited 2101 Beneficial owner
Shen Zhu 2501 Other
Ultimate Estate Limited 2201 Interest of corporation controlled by you
Treasure Partner International Limited 2501 Other
Gloryviewpharma Ltd 2501 Other
Honourpharma Ltd 2501 Other
Blesspharma Ltd 2501 Other

Jacobio Pharmaceuticals Group Co Headlines

No Headlines